Background: Anemia is inevitable as chronic kidney disease (CKD) advances. With the advent of erythropoietin-stimulating agents (ESAs), considerable improvement has been achieved in the management of anemia. However, some patients show a reduced response to ESAs. Methods: Many factors affect the response to ESA treatment. CKD is now considered as an inflammatory disorder and this understanding led to the recognition of the central role of inflammation in ESA resistance. Inflammation is related to untoward outcomes, including atherosclerosis and anemia, in the CKD population. Furthermore, recognition of deleterious effects of proinflammatory markers at different levels of erythropoiesis led to a change in the name of ‘anemia of chronic disease’ to anemia of inflammation. Results: The discovery of hepcidin as the major controller of iron metabolism in anemia of inflammation answered many questions regarding the interaction of erythropoietin, iron and bone marrow. Hepcidin production in the liver is driven by three major factors: inflammation, iron overload and anemia/hypoxia. Hepcidin levels are increased in patients with CKD due to the interaction of many factors; a comprehensive understanding of these pathways is thus critical in the effort to alleviate anemia of inflammation and ESA resistance. Conclusion: In this review, we discussed the epidemiology, determinants and consequences of anemia of inflammation in CKD patients with special emphasis on the central role of hepcidin along with molecular pathways driving its production.

Keywords:
Anemia, Inflammation, Chronic kidney disease
1.
Voormolen N, Grootendorst DC, Urlings TA, Boeschoten EW, Sijpkens YW, Huisman RM, et al: Prevalence of anemia and its impact on mortality and hospitalization rate in predialysis patients. Nephron Clin Pract 2010;115:c133–c141.
2.
Zarychanski R, Houston DS: Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ 2008;179:333–337.
3.
Asare K: Anemia of critical illness. Pharmacotherapy 2008;28:1267–1282.
4.
Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A: Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif 2010;29:1–12.
5.
Hsu CY, McCulloch CE, Curhan GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002;13:504–510.
6.
Astor BC, Muntner P, Levin A, Eustace JA, Coresh J: Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2002;162:1401–1408.
7.
Lacombe C: Resistance to erythropoietin. N Engl J Med 1996;334:660–662.
8.
Rao DS, Shih MS, Mohini R: Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993;328:171–175.
9.
Ono K, Hisasue Y: Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy. Clin Nephrol 1992;38:290–292.
10.
Stenvinkel P: Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif 2001;19:53–61.
11.
Bergstrom J, Lindholm B, Lacson E Jr, Owen W Jr, Lowrie EG, Glassock RJ, et al: What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 2000;13:163–175.
12.
Stenvinkel P, Barany P, Heimburger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int Suppl 2002;80:103–108.
13.
Kalantar-Zadeh K, Brennan ML, Hazen SL: Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2006;48:59–68.
14.
Qureshi AR, Alvestrand A, Divino-Filho JC, Gutierrez A, Heimburger O, Lindholm B, et al: Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002;13(suppl 1):S28–S36.
15.
Allen DA, Breen C, Yaqoob MM, Macdougall IC: Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-γ and TNF-α. J Investig Med 1999;47:204–211.
16.
Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreno V, et al: Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998;54:1337–1343.
17.
Trey JE, Kushner I: The acute phase response and the hematopoietic system: the role of cytokines. Crit Rev Oncol Hematol 1995;21:1–18.
18.
Jelkmann W: Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998;18:555–559.
19.
Faquin WC, Schneider TJ, Goldberg MA: Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987–1994.
20.
de Francisco AL, Stenvinkel P, Vaulont S: Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus 2009;2(suppl_1):i18–i26.
21.
Ganz T: Iron in innate immunity: starve the invaders. Curr Opin Immunol 2009;21:63–67.
22.
Cartwright GE, Lauritsen MA, Humphreys S, Jones PJ, Merrill IM, Wintrobe MM: The anemia of infection. II. The experimental production of hypoferremia and anemia in dogs. J Clin Invest 1946;25:81–86.
23.
De Domenico I, Ward DM, Langelier C, Vaughn MB, Nemeth E, Sundquist WI, et al: The molecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell 2007;18:2569–2578.
24.
Jenkins ZA, Hagar W, Bowlus CL, Johansson HE, Harmatz P, Vichinsky EP, et al: Iron homeostasis during transfusional iron overload in β-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression. Pediatr Hematol Oncol 2007;24:237–243.
25.
Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al: The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110:1037–1044.
26.
Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005;106:1864–1866.
27.
Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271–1276.
28.
Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, et al: In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 2010;116:3635–3644.
29.
Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, et al: Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPα. Blood 2008;111:5727–5733.
30.
Li H, Rose MJ, Tran L, Zhang J, Miranda LP, James CA, et al: Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J Pharmacol Toxicol Methods 2009;59:171–180.
31.
Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al: Hepcidin – a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051–1056.
32.
Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al: Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75:976–981.
33.
Barany P: Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 2001;16:224–227.
34.
Roy CN, Mak HH, Akpan I, Losyev G, Zurakowski D, Andrews NC: Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation. Blood 2007;109:4038–4044.
35.
Sasu BJ HM: Boone TC inventor Amgen Inc. Thousand Oaks, Calif assignee. Hepcidin, hepcidin antagonists and methods of use. USA patent US2008213277. September 2008.
36.
Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K: Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman’s disease (MCD). Blood 2010;116;3627–3634.
37.
Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, et al: Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010;95:505–508.
38.
Toba H, Nakashima K, Oshima Y, Kojima Y, Tojo C, Nakano A, et al: Erythropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond hematopoiesis. Clin Exp Pharmacol Physiol 2010;37:1139–1146.
39.
Huang H, Constante M, Layoun A, Santos MM: Contribution of STAT3 and SMAD4 pathways to the regulation of hepcidin by opposing stimuli. Blood 2009;113:3593–3599.
40.
Kong WN, Chang YZ, Wang SM, Zhai XL, Shang JX, Li LX, et al: Effect of erythropoietin on hepcidin, DMT1 with IRE, and hephaestin gene expression in duodenum of rats. J Gastroenterol 2008;43:136–143.
41.
Srai SK, Chung B, Marks J, Pourvali K, Solanky N, Rapisarda C, et al: Erythropoietin regulates intestinal iron absorption in a rat model of chronic renal failure. Kidney Int 2010;78:660–667.
42.
Shen Y, Wang Y, Li D, Wang C, Xu B, Dong G, et al: Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response. Transplant Proc 2010;42:1595–1597.
43.
Bian XX, Yuan XS, Qi CP: Effect of recombinant human erythropoietin on serum S100B protein and interleukin-6 levels after traumatic brain injury in the rat. Neurol Med Chir (Tokyo) 2010;50:361–366.
44.
Pavese I, Satta F, Todi F, Di Palma M, Piergrossi P, Migliore A, et al: High serum levels of TNF-α and IL-6 predict the clinical outcome of treatment with human recombinant erythropoietin in anaemic cancer patients. Ann Oncol 2010;21:1523–1528.
45.
Singh AK: What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens 2010;19:420–424.
46.
Ferrari P, Mallon D, Trinder D, Olynyk JK: Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton) 2010;15:344–349.
47.
Johnson DW, Hawley CM, Rosser B, Beller E, Thompson C, Fassett RG, et al: Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrol 2008;9:8.
48.
Morgan C, Zappitelli M, Gill P: Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review. Crit Care 2009;13:R165.
49.
Horiuchi Y, Hirayama S, Soda S, Seino U, Kon M, Ueno T, et al: Statin therapy reduces inflammatory markers in hypercholesterolemic patients with high baseline levels. J Atheroscler Thromb 2010;17:722–729.
50.
Sirken G, Kung SC, Raja R: Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. ASAIO J 2003;49:422–425.
51.
Arabul M, Gullulu M, Yilmaz Y, Akdag I, Kahvecioglu S, Eren MA, et al: Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease. Clin Biochem 2008;41:1055–1058.
52.
Li XY, Chang JP, Su ZW, Li JH, Peng BS, Zhu SL, et al: How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study. Ther Apher Dial 2010;14:308–314.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.